Literature DB >> 20956830

The impact of systemic therapy following ductal carcinoma in situ.

Jennifer Eng-Wong1, Joseph P Costantino, Sandra M Swain.   

Abstract

Following local therapy for ductal carcinoma in situ (DCIS), tamoxifen reduces the risk of ipsilateral and contralateral breast cancer by 30%-50%. Studies of tamoxifen in women with resected DCIS have not shown any effect on overall or cancer-specific survival. The adverse event profile of tamoxifen is well characterized, and individual risks and benefits should be assessed to guide decision making. We review the results of the phase III trials of tamoxifen in DCIS as well as the emerging risk reduction therapies.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20956830      PMCID： PMC4999067          DOI： 10.1093/jncimonographs/lgq021

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN： 1052-6773


  26 in total

1.  Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.

Authors:  Elizabeth Half; Xi Ming Tang; Karin Gwyn; Aysegul Sahin; Kyle Wathen; Frank A Sinicrope
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

2.  Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model.

Authors:  V C Jordan; K E Allen
Journal:  Eur J Cancer       Date:  1980-02       Impact factor: 9.162

3.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Authors:  Bernard Fisher; Joseph P Costantino; D Lawrence Wickerham; Reena S Cecchini; Walter M Cronin; Andre Robidoux; Therese B Bevers; Maureen T Kavanah; James N Atkins; Richard G Margolese; Carolyn D Runowicz; Joan M James; Leslie G Ford; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2005-11-16       Impact factor: 13.506

4.  Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Authors:  R Day; P A Ganz; J P Costantino; W M Cronin; D L Wickerham; B Fisher
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

5.  Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3.

Authors:  Kotha Subbaramaiah; Larry Norton; William Gerald; Andrew J Dannenberg
Journal:  J Biol Chem       Date:  2002-03-18       Impact factor: 5.157

Review 6.  National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.

Authors:  Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

7.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

Authors:  M Baum; A U Budzar; J Cuzick; J Forbes; J H Houghton; J G M Klijn; T Sahmoud
Journal:  Lancet       Date:  2002-06-22       Impact factor: 79.321

8.  Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma cell proliferation.

Authors:  J A Fontana
Journal:  Exp Cell Biol       Date:  1987

9.  Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results.

Authors:  E Shelley Hwang; Laura Esserman
Journal:  Ann Surg Oncol       Date:  2004-01       Impact factor: 5.344

10.  Retinoid-resistant estrogen receptor-negative human breast carcinoma cells transfected with retinoic acid receptor-alpha acquire sensitivity to growth inhibition by retinoids.

Authors:  M S Sheikh; Z M Shao; X S Li; M Dawson; A M Jetten; S Wu; B A Conley; M Garcia; H Rochefort; J A Fontana
Journal:  J Biol Chem       Date:  1994-08-26       Impact factor: 5.157
View more
  5 in total

1.  Effect of infertility treatment and pregnancy-related hormones on breast cell proliferation in vitro.

Authors:  Anne Cooley; Laura Matthews; Stanislav Zelivianski; Ashley Hardy; Jacqueline S Jeruss
Journal:  Hum Reprod       Date:  2011-11-10       Impact factor: 6.918

2.  Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status.

Authors:  Gaiane M Rauch; Henry M Kuerer; Marion E Scoggins; Patricia S Fox; Ana P Benveniste; Young Mi Park; Sara A Lari; Brian P Hobbs; Beatriz E Adrada; Savitri Krishnamurthy; Wei T Yang
Journal:  Breast Cancer Res Treat       Date:  2013-06-18       Impact factor: 4.872

3.  Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review.

Authors:  Sara A Lari; Henry M Kuerer
Journal:  J Cancer       Date:  2011-05-01       Impact factor: 4.207

4.  Molecular subtypes predict second breast events of ductal carcinoma in situ after breast-conserving surgery.

Authors:  Yilan Yang; Xu Zhao; Xuanyi Wang; Kairui Jin; Jurui Luo; Zhaozhi Yang; Xin Mei; Jinli Ma; Zhimin Shao; Zhen Zhang; Xingxing Chen; Xiaomao Guo; Xiaoli Yu
Journal:  Cancer Med       Date:  2022-05-22       Impact factor: 4.711

5.  Tamoxifen Initiation After Ductal Carcinoma In Situ.

Authors:  Hazel B Nichols; Erin J A Bowles; Jessica Islam; Lawrence Madziwa; Til Stürmer; Diem-Thy Tran; Diana S M Buist
Journal:  Oncologist       Date:  2016-01-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.